Spots Global Cancer Trial Database for A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
Official Title: A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
Study ID: NCT01703572
Interventions
Study Description
Brief Summary: This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UC San Diego Moores Cancer Center, La Jolla, California, United States
University of Colorado Hospital, Anschutz Cancer Pavilion, Aurora, Colorado, United States
UF Health Davis Cancer Pavilion and Shands Med Plaza, Gainesville, Florida, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Cornell University Division of Hematology and Medical Oncology, New York, New York, United States
NYU Clinical Cancer Center, New York, New York, United States
University of Rochester Medical Center, Rochester, New York, United States
Duke Cancer Institute, Durham, North Carolina, United States
Sara Cannon Research Institute, Nashville, Tennessee, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
